Literature DB >> 31255334

Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial.

Mark E Cooper1, Silvio E Inzucchi2, Bernard Zinman3, Stefan Hantel4, Maximilian von Eynatten5, Christoph Wanner6, Audrey Koitka-Weber7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31255334     DOI： 10.1053/j.ajkd.2019.03.432

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  13 in total

Review 1.  Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering.

Authors:  Brendon L Neuen; David Z Cherney; Meg J Jardine; Vlado Perkovic
Journal:  CMAJ       Date:  2019-10-15       Impact factor: 8.262

2.  Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial.

Authors:  Muthiah Vaduganathan; Silvio E Inzucchi; Naveed Sattar; David H Fitchett; Anne Pernille Ofstad; Martina Brueckmann; Jyothis T George; Subodh Verma; Michaela Mattheus; Christoph Wanner; Bernard Zinman; Javed Butler
Journal:  Diabetes Obes Metab       Date:  2021-10-07       Impact factor: 6.408

Review 3.  Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Nat Rev Endocrinol       Date:  2020-08-27       Impact factor: 43.330

4.  Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial.

Authors:  Adeera Levin; Vlado Perkovic; David C Wheeler; Stefan Hantel; Jyothis T George; Maximilian von Eynatten; Audrey Koitka-Weber; Christoph Wanner
Journal:  Clin J Am Soc Nephrol       Date:  2020-09-29       Impact factor: 8.237

5.  Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.

Authors:  Bruce A Perkins; Nima Soleymanlou; Julio Rosenstock; Jay S Skyler; Lori M Laffel; Karl-Heinz Liesenfeld; Dietmar Neubacher; Matthew M Riggs; Curtis K Johnston; Rena J Eudy-Byrne; Ahmed Elmokadem; Jyothis T George; Jan Marquard; Valerie Nock
Journal:  Diabetes Obes Metab       Date:  2020-01-21       Impact factor: 6.577

Review 6.  Renal physiology of glucose handling and therapeutic implications.

Authors:  David Z Cherney; Mehmet Kanbay; Julie A Lovshin
Journal:  Nephrol Dial Transplant       Date:  2020-01-01       Impact factor: 5.992

Review 7.  Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?

Authors:  Brendon L Neuen; Meg J Jardine; Vlado Perkovic
Journal:  Nephrol Dial Transplant       Date:  2020-01-01       Impact factor: 5.992

8.  Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.

Authors:  Darren K McGuire; Weichung J Shih; Francesco Cosentino; Bernard Charbonnel; David Z I Cherney; Samuel Dagogo-Jack; Richard Pratley; Michelle Greenberg; Shuai Wang; Susan Huyck; Ira Gantz; Steven G Terra; Urszula Masiukiewicz; Christopher P Cannon
Journal:  JAMA Cardiol       Date:  2021-02-01       Impact factor: 14.676

Review 9.  Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors.

Authors:  Davide Margonato; Giuseppe Galati; Simone Mazzetti; Rosa Cannistraci; Gianluca Perseghin; Alberto Margonato; Andrea Mortara
Journal:  Heart Fail Rev       Date:  2020-09-08       Impact factor: 4.214

Review 10.  Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease.

Authors:  Tamara Y Milder; Sophie L Stocker; Richard O Day; Jerry R Greenfield
Journal:  Drug Saf       Date:  2020-10-23       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.